.jpg)
3.Comparison of Therapies to Reduce Total Cholesterol and Glucose Levels in Type II Diabetics
Ghazal Raza1, Muhammad Sajid Abbas Jaffri2 and Shabih Zehra3
ABSTRACT
Objective: To compare the effectiveness of high dose pitavastatin and intermediate dose pitavastatin combined with ezetimibe in lowering total cholesterol (TC) in diabetic patients on metformin. Secondary endpoint is to compare glycosylated hemoglobin (HbA1c) levels after therapy.
Study Design: Observational / comparative study
Place and Duration of Study: This study was conducted at the NMC and PNS Shifa Hospitals from January 2022 to June 2022.
Materials and Methods: Patients diagnosed according to international guidelines were included in the study. Consultation was conducted by physicians; glycosylated hemoglobin and lipid tests were performed in pathology labs of the above-mentioned hospitals before and after intervention.
Results: Sample of 50 individuals was divided into two groups of 25 patients. HbA1c and TC levels were assessed before and after 3 months of therapy. TC was significantly higher in group A compared to group B after treatment (U = 172.5, p = 0.006). Mean TC after therapy dropped to 73.7±18 mg/dl, a change of 64.9% in group A and to 60.7±15.6 mg/dl, a 67.83% change in group B. HbA1c was marginally higher in group B compared to group A after therapy (U = 311, p = 0.981).
Conclusion: Metformin-pitavastatin (2 mg)-ezetimibe lowered TC levels significantly in type II diabetics compared to metformin-pitavastatin (4 mg) group. HbA1c dropped considerably in both groups, but the difference was not statistically significant.
Key Words: pitavastatin, ezetimibe, total cholesterol, type II diabetes, glycosylated hemoglobin, metformin.